Navigation Links
Optimized Dengue RT-PCR

le lane 9 is water (template negative) control. Discussion

Lanciotti et al. (1992) designed the primers using prototype dengue virus strains Den-1 (Hawaii), Den-2 (New Guinea C), Den-3 (H-87) and Den-4 (H-241). In addition, they also included 33 virus isolates from different geographical regions to test the efficiency of their designed primers. According to their paper, only a single PCR product of 511 bp in length was amplified. In our study we also detected, in addition to the target PCR product, the presence of another PCR product measuring at 190 bp. In the beginning, we had assumed that this extra band was a non-specific PCR product.

However, by experimenting at various different annealing temperatures ranging from 56.4C to 72C in our PCR by using Eppendorf's Mastercycler gradient, we found that the 190 bp product persisted in all the different annealing temperatures wheras the target PCR product (511 bp) was not detected at 72C.This could indicate that the primers used by Lanciotti et al. (1992) annealed at least at 2 sites (repeat sequence?) for this particular strain (Vietnamese B98). We hope to sequence this strain to identify the genotype.

Reference

Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV (1992). Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. Journal of Clinical Microbiology, 30(3) 545-551


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Optimized Imaging of Protein Gels Stained with Coomassie Brilliant Blue Dye
2. Eagle Eye Optical Filter Optimized for Imaging Silver-Stained Gels
3. Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys
4. New Kit Generates Exceptionally Pure Total RNA for RT-PCR
5. Brilliant Core Reagent Kits for QPCR and QRT-PCR
6. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
7. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
8. Performance Comparisons of Commercial RT-PCR Systems
9. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
10. RT-PCR Primers for the Study of Apoptosis
11. cMaster RTplusPCR System for increased sensitivity and product length in RT-PCR
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Optimized Dengue PCR

(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... 86 percent and a narrowed net loss for its fiscal ... business, government and education. , ,Revenue for 2005 was $8.3 ... had a $4.2 million net loss, a slight improvement over ... the effect of the firm's growth phase, which also involved ...
... , ,Of the approximately 12,000 people who are diagnosed with ... year, and the rest within 3 years. The only treatments ... the tumor and radiation treatment with the maximum tolerated dose ... of life. Because of this, researchers are racing to find ...
... and angel investors has been "cleaned up" to make ... Act 255 is an incentives package for investors ... apply for tax credits of 25 percent of their ... by the governor on Wednesday, allows groups of investors, ...
Cached Biology Technology:Radiology advance points way to non-invasive brain-cancer treatment 2
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... Laboratory is working closely with Chinese scientists and ... cleaner Beijing and developing sustainable technologies for the ... DOE and China,s Ministry of Science and Technology ... scale deployment of next-generation vehicle technologies. The benefits ...
... One day soon, laboratories may grow synthetically engineered tissues ... a major step forward, Cornell engineers describe in the ... have developed that can nourish growing tissues., The researchers ... mimic a vascular system at the cellular scale and ...
... Capecchi, Ph.D., distinguished professor of human genetics and biology ... Genetics and a Howard Hughes Medical Institute investigator, has ... The announcement was made this morning by the ... The prize recognizes Capecchis pioneering development of knockout mice ...
Cached Biology News:Argonne helps China create cleaner Beijing for 2008 Olympics 2Researchers create system to build transplant tissue 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 2Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine 3
... uses three Adept CE 4100 high pressure ... rate in one microlitre increaments. The ... provides added flexibility. The WaveQuest ... array detection and provides superior stability . ...
... of samples may be carried out using this ... System control and data processing is provided ... The elegant, powerful and very easy to use ... and 2000., The supplied detector is the ground ...
...
capacity 250 mL...
Biology Products: